Influx Healthtech IPO: Strong Demand on Day 1!

Influx Healthtech IPO: Strong Demand on Day 1!

The ₹55.63 crore SME IPO of Influx Healthtech opens to investor interest amid solid grey market premium; analysts watch subscription numbers and market sentiment for early cues.

Summary:
Influx Healthtech launched its initial public offering (IPO) on June 18, targeting ₹55.63 crore via the SME route. The initial public offering (IPO), valued between ₹91 and ₹96 per share, is set to close on June 21, with shares expected to start trading on the NSE SME on June 25. Early interest, reflected in grey market premiums, suggests investor optimism. This article explores key IPO details, valuation, GMP trends, risk factors, and what investors should watch before applying.

IPO Overview: Influx Healthtech Hits the Market
Influx Healthtech Limited, a technology-focused company in the healthcare industry, launched its SME IPO for public subscription on June 18, 2025. The firm aims to raise ₹55.63 crore through a fresh issuance of equity shares. The price range is set between ₹91 and ₹96 per share, with investors able to bid in lots of 1,200 shares, requiring a minimum investment of ₹1,15,200 at the upper end of the price band.
The IPO will be open for subscription until June 21. Allotment details will be finalized by June 23, and shares are anticipated to be credited to demat accounts by June 24. The company’s shares are expected to start trading on the NSE SME platform on June 25.

Company Profile: A Tech-Driven Healthcare Innovator
Influx Healthtech Limited operates at the intersection of technology and healthcare, offering a suite of health-tech services ranging from AI-powered diagnostics, telemedicine platforms, to digital patient management systems. The company focuses on digitizing the healthcare value chain by working with hospitals, diagnostic labs, and individual practitioners.
Their platforms aim to solve key inefficiencies in the healthcare sector, such as patient engagement, appointment scheduling, and diagnostic result delivery. Given the rising demand for healthcare digitization in India and globally, Influx Healthtech is attempting to tap into a high-growth niche.

IPO Structure and Utilization of Proceeds
The ₹55.63 crore IPO is a 100% fresh issue, with no offer for sale (OFS) component. This means that all the proceeds will directly go to the company for its growth and expansion plans. According to the red herring prospectus:
₹20 crore will be used for technology upgradation and product development.
₹15 crore is allocated for marketing and client acquisition.
₹10 crore for infrastructure expansion, including setting up regional offices.
The remaining funds will go towards working capital and general corporate purposes.

Financials Snapshot
As per the company’s financial disclosures:
Revenue for FY24 stood at ₹35.8 crore, up from ₹24.3 crore in FY23 — a YoY growth of 47%.
Profit After Tax (PAT) rose to ₹6.9 crore in FY24 from ₹4.1 crore in FY23.
The company has achieved a robust EBITDA margin of 18.6%, highlighting its operational efficiency.
Debt levels are minimal, improving their financial risk profile ahead of listing.

Grey Market Premium (GMP) and Market Sentiment
As of Day 1, market observers report a Grey Market Premium (GMP) of ₹20–₹24 per share, indicating that the IPO is likely to list at a premium of 20–25% over the upper price band of ₹96.
The GMP trend reflects strong investor confidence and favourable sentiment towards tech-enabled SME companies. However, investors must be cautious as GMP is unofficial and speculative in nature.

Key Dates to Remember
EventDate
IPO Opening Date June 18, 2025
IPO Closing Date June 21, 2025
Basis of Allotment June 23, 2025
Credit of Shares June 24, 2025
Listing on NSE SME June 25, 2025

Valuation & Peer Comparison
At the upper price band of ₹96, Influx Healthtech is valued at a P/E ratio of around 20x based on FY24 earnings. This valuation is competitive when compared to other tech-based SMEs in the health sector, such as Docmode Health or Medtech Solutions, which are trading at P/E multiples of 25–30x.
Analysts suggest that while the valuation appears reasonable, growth sustainability and execution in the B2B health-tech domain will be critical for long-term gains.

Risk Factors to Consider
Despite the strong growth trajectory, investors should note the following risks:
Client concentration risk – a significant portion of revenue comes from a handful of hospital networks.
Tech dependency – any breach, bug, or tech downtime could significantly impact operations.
Regulatory challenges in healthcare data privacy and compliance could arise with scale.
Limited track record – while growth is visible, the company is still in the early stages of scale.

Analyst Views
Brokerage firms tracking the SME IPO space have issued a “Subscribe with Caution” recommendation. While the company’s strong growth, lean balance sheet, and sectoral tailwinds are promising, the relatively short operating history and high competitive intensity in health tech raise concerns.
Retail investors with a moderate risk appetite and long-term view may consider subscribing to the issue.

Conclusion
Influx Healthtech’s IPO comes at a time when digital transformation in the healthcare industry is accelerating. With a niche presence, healthy financials, and reasonable pricing, the IPO has generated justified market interest. However, investors must weigh the growth prospects against sector-specific risks and evolving regulatory frameworks.

:

:

The image added is for representation purposes only